Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2014

View Archived Issues

Structure-based development of novel bromodomain and extra-terminal domain inhibitors

New mechanism of action for small-molecule antidiabetic drugs reported

Isarna Therapeutics and Santaris Pharma to develop next-generation oligonucleotides

Insight Genetics given phase II NCI contract for lung cancer resistance test

Bayer and Peking University establish new research center in Beijing

XTL Biopharmaceuticals in-licenses hCDR1 for lupus

BioDefense Therapeutics enrolls first patient in phase III trials of favipiravir

OxiGene presents results from a phase I trial evaluating OXi-4503 in patients with AML and MDS

Researchers present phase I results for 225Ac-lintuzumab in older patients with AML

MedImmune and Immunocore enter agreement to develop cancer therapies

Polish researchers divulge new amphotericin B derivatives for fungal infections

DiaMedica begins phase II trial of DM-199

GlaxoSmithKline presents a novel antibody-drug conjugate for the treatment of multiple myeloma

University of Massachusetts Medical School to develop PiZ antibody for the Alpha-1 Project

AC Immune raises funds and initiates trial of vaccine candidate for Alzheimer's disease

Neurovance reports interim data from phase IIIa pilot study of EB-1020 SR

FDA grants QIDP and fast track status to amikacin fosfomycin inhalation system

Sunesis Pharmaceuticals expands hematology pipeline with two kinase inhibitor programs

Vertex reports first data from study of VX-135 in combination with daclatasvir

Neurocrine reports 12-week results from phase IIb study of tardive dyskinesia candidate

PaxVax discloses interim results from phase III study of single-dose oral cholera vaccine candidate

Avelas Biosciences raises funds to advance real-time cancer visualization technology

Vanderbilt University patent divulges novel mGlu5 receptor PAMs

Sunovion researchers prepare and test PDE10A inhibitors

Sanofi reports development of PIK3C3 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...